Posted by AGORACOM-JC
at 10:39 AM on Wednesday, November 20th, 2019
SPONSOR: PRIMO NUTRACEUTICALS INC.
(CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV)
provides strategic capital to the thriving cannabis cultivation
sector through ownership and development of commercial real estate
properties. The company also offers fully built out turnkey facilities
equipped with state-of-the-art growing infrastructure to cannabis
growers and processors. Click here for more info.
PODCAST: Hemp, CBD And Cannabis With Josh Drayton And Alex Seleznov
Summary
Josh Drayton is Communications and Outreach Director of the
California Cannabis Industry Association, an association that
collectively represents over 460 industry businesses.
Alex Seleznov is a board member and Treasurer for the National Hemp
Association as well as founder of Advanced Extraction, a company
specializing in organically produced hemp products.
They join the show today to discuss why everyone’s paying attention
to California, the preventable vaping crisis and what it means to be in
the current CBD space.
6:45 – Josh has worked at CCIA for 4 years. Getting to know cannabis
as an economic driver and way of life. Passionate about legalization.
7:25 – Issues with California policy. Looking at the timeline.
Legalized medical in 1996 but no state regulations. No statewide
framework until 2013, which is when CCIA formed. 2016 adult use passed
in California and the past few years have seen medical and adult use
regulations being figured out. 55 bills in this year alone. Everyone’s
paying attention to California but it takes being incredibly engaged.
9:55 – Licensing supply and demand. Dual licensing system in
California (local and state permits). Conflicting regulations in
different areas.
11:15 – Regulated vs. illicit shops. Lack of education about black
market. Plays into the vaping crisis. Needs to improve. Deaths in
California happened in banned areas from black market. War on drugs
doesn’t improve public health. Legislators beginning to understand this.
13:35 – Prediction for federal legality. Will California be a model?
California modeled itself on other successful markets and has gone above
and beyond in regards to packaging and testing regulations. Federal
government is watching California. Canada, France, New Zealand, Germany
regulators all have toured California to see how their cannabis market
works. SAFE Banking Act a huge catalyst. Regulating gives more control,
not less.
15:23 – Farm Bill passing, CBD proliferation has helped THC market. Medical conversations help with cannabis and hemp markets.
16:40 – Investors interested in getting into the space – everyone
needs to understand it’s a marathon, not a sprint. The longer the legal
market exists the more it’s going to pay off.
17:25 – Alex’s company Advanced Extractions. Vertically integrated hemp/CBD company based in Colorado.
18:25 – Confusion around passage of Farm Bill in CBD space. What it
means to be in the CBD space right now. Lack of regulation means people
are interpreting rules on their own. Lots of opportunity.
19:49 – What do investors and consumers need to look for in this
space? Investors need to vet claims a company makes. Only FDA demand is
on claims. Transparency is key as well as evidence of regulatory
compliance. Market is subject to scrutiny that no other product – no
matter how harmful – is subject to.
22:05 – Differentiation in a saturated market. Restricted marketplace gives opportunity for brands to find their niche.
23:52 – Future of hemp space. Total plant purposes of hemp. Putting
more renewables into the consumer stream. Alternative to plastic.
Initially there will be more of a ceiling before it’s able to become a
mass market product.
Tags: CBD, CSE, Hemp, Marijuana, stocks, tsx, tsx-v, weed Posted in PRIMO Nutraceuticals Inc. | Comments Off on PRIMO Nutraceuticals Inc. $PRMO.ca – PODCAST: #Hemp, #CBD And #Cannabis With Josh Drayton And Alex Seleznov $CROP.ca $VP.ca NF.ca $MCOA
Posted by AGORACOM-JC
at 8:39 AM on Wednesday, November 20th, 2019
Company has launched commissioned based sales personnel and an influencer strategy for it’s Sollievo CBD line in Southern California
In addition, the Heritage CSE: CANN previously announced proposed joint venture initiative, is proceeding forward as planned with the definitive agreement drafting taking place and facility and equipment procurement plans underway.
VANCOUVER, Nov. 20, 2019 - EMPOWER CLINICS INC. (CSE: CBDT) (Frankfurt 8EC) (OTC: EPWCF) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company, and a multi-state operator of medical health & wellness clinics in the U.S., is pleased to announce the Company has launched commissioned based sales personnel and an influencer strategy for it’s Sollievo CBD line in Southern California. In addition, the Heritage CSE: CANN previously announced proposed joint venture initiative, is proceeding forward as planned with the definitive agreement drafting taking place and facility and equipment procurement plans underway.
The California population is 39,557,045 people according
to the US Census Bureau’s 2018 Population Estimates Program making it
the most populated state in the U.S. Los Angeles County, Orange County and Ventura County have a combined population of 14,149,511 consumers making it one of the most densely populated regions of the entire country.
The California Cannabis Portal indicates there are over 170 dispensaries in Los Angeles County
that our sales agents are canvassing and bringing Sollievo product
samples too. They are also talking to various smoke shops, vape stores
and a variety of retail locations that carry CBD products or have
expressed an interest to sell CBD products.
“Establishing a retail presence in this area for our Sollievo CBD
product lines gives us significant volume potential, but also provides
crucial market feedback about branding, product quality and consumer
adoption.” said Steven McAuley, Empowers Chairman and CEO.
“Gaining direct market feedback, by having our own sales agents on the
ground is already proving beneficial.”
Heritage Cannabis JV Update
The previously announced Empower Clinics and Heritage Cannabis JV announcement from September 17th, 2019 is continuing forward as planned with a variety of actions being completed by both Parties.
Documentation of the Definitive Agreement for the joint venture is
underway, and progress is expected to be reported by the Companies in
the near future.
Graeme Staley, the CEO of Purefarma and Board of Directors member for Heritage Cannabis, completed a site visit of the Sandy, OR facility located on the SE side of Portland, Oregon with Empowers Chairman & CEO Steven McAuley.
The site visit solidified the importance of the new 5,000 sq. ft.
facility secured by Empower, and the fact that the Oregon Department of
Agriculture Hemp Handlers Licence has been issued.
Both Empower and Heritage believe operating in a low-cost region like Oregon
provides a competitive advantage with direct access to the farming
supply chain for the some of the best hemp biomass in the entire
country.
Local facility and labor costs are competitive on a national scale,
and with a skilled and passionate local workforce, the joint venture has
the opportunity to provide high quality long-term jobs for the local
economy of Sandy, OR, Clackamas County and surrounding regions.
ABOUT EMPOWER
Empower is a vertically integrated and growth-oriented CBD life
sciences company, and a multi-state operator of medical health &
wellness clinics, operating the Sun Valley Health clinic brand www.sunvalleyhealth.com, for its nine corporate locations and for franchises in the United States.
As a CBD product manufacturer under the Sollievo brand, the Company
distributes its lines through clinics, online and through retail
partners. Extraction operations are currently being developed in the
Company’s new extraction facility in Oregon.
ABOUT HERITAGE
The Company is a vertically integrated cannabis provider that
currently has two Health Canada approved licenced producers, through its
subsidiaries Voyage Cannabis Corp. and CannaCure Corp. both regulated
under the Cannabis Act Regulations. Working under these two licences,
Heritage has two additional subsidiaries, Purefarma Solutions, which
provides extraction services, and BriteLife Sciences that is focused on
cannabis based medical solutions. Heritage as the parent Company, is
focused on providing resources for its subsidiaries to advance their
products or services to compete both domestically and internationally.
ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley Chief Executive Officer
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain “forward-looking statements”
or “forward-looking information” (collectively “forward looking
statements”) within the meaning of applicable Canadian securities laws. All
statements, other than statements of historical fact, are
forward-looking statements and are based on expectations, estimates and
projections as at the date of this news release. Forward-looking statements
can frequently be identified by words such as “plans”, “continues”,
“expects”, “projects”, “intends”, “believes”, “anticipates”,
“estimates”, “may”, “will”, “potential”, “proposed” and other similar
words, or information that certain events or conditions “may” or “will”
occur. Forward-looking statements in this news release include
statements regarding; the Company’s intention to open a hemp-based CBD
extraction facility, the expected benefits to the Company and its
shareholders as a result of the proposed acquisitions and partnerships;
the terms of the proposed acquisitions and partnerships; the
effectiveness of the extraction technology; the expected benefits for
Empowers patient base and customers; the benefits of CBD based products;
the effect of the approval of the Farm Bill; the growth of the
Company’s patient list and that the Company will be positioned to be a
market-leading service provider for complex patient requirements in 2019
and beyond. Such statements are only projections, are based on
assumptions known to management at this time, and are subject to risks
and uncertainties that may cause actual results, performance or
developments to differ materially from those contained in the
forward-looking statements, including; that the Company may not open a
hemp-based CBD extraction facility; that the hemp-based CBD extraction
facility may not be fully operational in 2019 if at all; that
legislative changes may have an adverse effect on the Company’s business
and product development; that the Company may not be able to obtain
adequate financing to pursue its business plan; general business,
economic, competitive, political and social uncertainties; failure to
obtain any necessary approvals in connection with the proposed
acquisitions and partnerships; and other factors beyond the Company’s
control. No assurance can be given that any of the events anticipated by
the forward-looking statements will occur or, if they do occur, what
benefits the Company will obtain from them. Readers are cautioned not to
place undue reliance on the forward-looking statements in this release,
which are qualified in their entirety by these cautionary statements.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements in this release, whether as a result of new information,
future events or otherwise, except as expressly required by applicable
laws.
CONTACTS: Investors: Steve Low, Boom Capital Markets, [email protected], 647-620-5101; Investors: Steven McAuley, CEO, [email protected], 604-789-2146; For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARICopyright CNW Group 2019
Tags: CSE, Hemp, Marijuana, stocks, tsx, tsx-v, weed Posted in Empower Clinics Inc. | Comments Off on Empower $CBDT.ca launches #CBD product sales strategy in California and provides progress report on Heritage Joint Venture for Extraction and Production Facility in Oregon $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca
Posted by AGORACOM-JC
at 5:10 PM on Tuesday, November 19th, 2019
Empower Clinics JV Could Generate $US 30,000,000 In Annual Revenue From CBD Extraction … But It Doesn’t End There
With 165,000 patients, Empower Clinics (CBDT:CSE) (EPWCF:OTCQB) has a database that almost every medical cannabis and CBD company would kill for. Add in the fact it is now on a ~ $USD 4,000,000 annualized revenue run rate for 2019 and it becomes the kind of company small cap investors have been dying to find as they watch pretender companies melt away.
But it doesn’t end there.
The Company’s latest Q3 financials show that Empower is in full growth mode, with substantial increases in revenue and patient visits, as well as, big reductions in expenses. Moreover, Company CEO Steven McAuley says growth will continue full steam ahead in Q4, Q1 and beyond.
But it doesn’t end there.Â
CBD extraction has been a key element of the company’s vertical integration. Producing its’ own hemp-derived CBD products for its own massive patient list just makes sense. However, thanks to an LOI (moving towards definitive agreement) to JV with extraction experts Heritage Cannabis, the Company’s 5,000 sq ft facility in Oregon is also planning to serve big brand 3rd party partners in the USA . Empower brings the infrastructure, Heritage brings the expertise and balance sheet. The result is a match made in shareholder heaven with initial annual capacity of 6,000 Kg at ~ $US 5,000 per Kg, which adds up to $US 30,000,000 in potential revenue.
We emphasize potential  because nobody has started selling anything yet but the facility is expected to begin producing soon. However, with a built in patient database and talks already having commenced for white label products, Empower is on its way. Moreover, “potential” cuts both ways, with capacity capable of increasing 2x – 3x without much trouble given the size of the facility. Â
Can Empower successfully execute its extraction plan? It’s a legitimate question, with a blow away answer.. The Company’s new CEO, Steven McAuley, who replaced the previous management team in January, is Six Sigma certified under the quality initiative of legendary GE chairman Jack Welch. We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never …. which also explains how McAuley has brought Empower to such heights in just 11 months.
The cannabis market is currently throwing away babies with the bathwater – but just as the dot-com crash brought us massive riches through Web 2.0 companies that were REAL, investors need to start looking for the REAL companies that will survive and thrive. With 165,000 patients, rapidly increasing revenues, a franchise plan to grow clinics across America and a vertical integration CBD extraction strategy to tie them all together, Empower Clinics may be such a company. Â
Grab your favourite beverage and settle in to watch what may be your next great small cap investment.
Posted by AGORACOM-JC
at 8:59 AM on Tuesday, November 19th, 2019
Signed a definitive asset purchase agreement to acquire all assets of Nevada Botanical Science, Inc.
Transaction valued at USD$7.5Â million
NBS currently operates a 5,000 sq. ft. indoor cultivation facility and has been approved for expansion of up to 60,000 sq. ft of greenhouse space.
Property also includes an operating extraction facility and licensed and approved commercial kitchen.
This infrastructure is capable of manufacturing and bottling beverages and edibles and is currently used by NBS for both white label and branded product manufacturing.
TORONTO, Nov. 19, 2019 — North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company”) is pleased to announce that Bonfire Brands USA, a wholly owned subsidiary of NORTHBUD, has signed a definitive asset purchase agreement to acquire all assets of Nevada Botanical Science, Inc. (“NBSâ€) (see June 25, 2019 press release) in a transaction valued at USD$7.5 million.
Nevada Botanical Science (NBS) is located in Reno, Nevada. NBS holds
Nevada State medical and adult use licenses for cultivation, extraction
and distribution. NBS operates an integrated cannabis operation located
on 3.2 acres of land within the Reno green zone industrial park. NBS
currently operates a 5,000 sq. ft. indoor cultivation facility and has
been approved for expansion of up to 60,000 sq. ft of greenhouse space.
The property also includes an operating extraction facility and licensed
and approved commercial kitchen. This infrastructure is capable of
manufacturing and bottling beverages and edibles and is currently used
by NBS for both white label and branded product manufacturing. Operated
by healthcare professionals, NBS has been primarily focused on the
Nevada State medical cannabis market. NBS currently manufactures and
sells award winning (Jack Herer Cup 2018) topical pain creams, balms and
lotions under the Trichomic medical brand.
This past year NBS launched a trial release of cannabis infused
cocktails under the brand “Happiest Hourâ€. Collaborating with local
craft beverage manufactures NBS released a variety of beverages
including Margarita, Pina Colada, Bloody Mary, Long Island Ice Tea and
Lemonade to select retailers in the state. To date retailer adoption and
reordering has been 100% and based on customer feedback, NBS will
increase production and distribution including additional retailers in
Las Vegas in 2020. NBS has also finished a successful trial launch of
its energy shot 1oz beverage containing 25mg of THC and 50mg of
Caffeine. The Company plans to run a second branded trial in early 2020.
Over the past three months NBS and NORTHBUD have been working together
in preparation for the release of NORTHBUD branded dried flower products
in Q4 2019 and a variety of infused and non-infused pre rolls.
“Subject to the finalizing of the previously announced acquisition of
the Qlora Group in California, the Company plans to establish a unified
product manufacturing and distribution platform within these two
important states,†said Justin Braune, President of Bonfire Brands USA.
“The license classes in California and Nevada allow for identical
activities and the Company has been in negotiation with multiple
potential JV partners who wish to leverage this unique platform. Being
one of the few multi state operators with operations in both states will
allow us to offer turnkey solutions to prospective partners moving
forward.â€
Transaction Terms
The transaction (the “Transactionâ€) is structured as an asset
purchase agreement whereby in exchange for the purchase of all of the
securities and assets of NBS, NORTHBUD is paying a total of
USD$7,500,000 as follows:
Cash payment of USD$500,000 (paid in full);
Approximately USD$1 million in convertible shares of Bonfire Brands USA (6,500,000 “convertible sharesâ€); and
A USD$6,000,000 interest bearing promissory note.
The convertible shares may be exchanged on a 1-1 basis with common
shares of NBUD at the discretion of the shareholder. At the time of
signing, the converted value of these securities was equal to
USD$1,000,000. All applicable U.S. and Canadian regulatory holds shall
apply upon conversion.
As per the terms of the agreement NBS will allocate pro rated
ownership of assets in NBS and all associated licenses to Bonfire Brands
USA throughout the re-payment period, subject to state approval.
Bonfire Brands and NBS have agreed to an operations and management
arrangement allowing Bonfire to assume operational control, begin
integration and driving revenue immediately.
“The NORTHBUD and Bonfire Brands USA team are extremely proud to have
finalized this agreement making the state of Nevada our strategic entry
point into the U.S. legal cannabis market,†said Ryan Brown, CEO of
NORTHBUD. “We are equally proud of the structure of the deal and how it
minimizes shareholder dilution while allowing our team to begin
integration and operations with a focus on immediate revenue growth in
one of the most sought-after adult use markets in North America. Our
team has been looking at acquisitions in Nevada for over two years
before finding the right fit. The Nevada market is considered one of
the largest and most profitable in North America with recreational sales
of USD$580 million in the first full year of legalization* (2017 Nevada
Dept. of Taxation).â€
The securities of the Company have not been and will not be
registered under the United States Securities Act of 1933, as amended
(the “U.S. Securities Actâ€) or any state securities
laws. Accordingly, the securities of the Company may not be offered or
sold within the United States unless registered under the U.S.
Securities Act and applicable state securities laws or pursuant to an
exemption from the registration requirements of the U.S. Securities Act
and applicable state securities laws. This news release does not
constitute an offer to sell or a solicitation of an offer to buy any of
the securities of the Company in any jurisdiction in which such offer,
solicitation or sale would be unlawful.
The Transaction is a significant acquisition but will not result in a
“Fundamental Change†pursuant to the policies of the CSE. NORTHBUD will
be preparing the necessary corporate and securities filings in order to
secure the required approvals for the Transaction.
The parties have agreed to pay USD$187,500 in broker/finder fees to
arm’s length parties on a prorated basis connection with the closing of
the Transaction.
The closing of the Transaction is conditional on the receipt by the
parties of applicable corporate and regulatory approvals, including that
of the CSE.
About Nevada Botanical Science, Inc.
Founded by a group of northern Nevada physicians and healthcare
professionals who believe in the promise of medical cannabis, Nevada
Botanical Science has developed a world class cannabis production,
research and development facility in Reno’s Washoe County. Its work and
commitment are fully in compliance with the Hippocratic Oath as well as
Nevada statute. Nevada Botanical Science is dedicated to ensuring the
highest measure of safety, governance and stewardship for its patients,
employees and the community it serves.
North Bud Farms Inc., through its wholly owned subsidiary GrowPros
MMP Inc., is pursuing a licence under The Cannabis Act. The Company has
built a state-of-the-art purpose-built cannabis production facility
located on 135 acres of Agricultural Land in Low, Quebec, Canada.
NORTHBUD through its wholly owned U.S. subsidiary, Bonfire Brands USA
has acquired Nevada Botanical Science, Inc. a world class cannabis
production, research and development facility with 5,000 sq. ft. of
indoor cultivation in Reno’s Washoe County. Nevada Botanical Science
holds medical and adult use licenses for cultivation, extraction and
distribution. Bonfire Brands USA has entered into an agreement to
acquire assets in Salinas, California.
Neither the Canadian Securities Exchange (the “CSEâ€) nor its
Regulation Services Provider (as that term is defined in the policies of
the CSE) accepts responsibility for the adequacy or accuracy of this
release.
Forward-looking statements Certain statements and
information included in this press release that, to the extent they are
not historical fact, constitute forward-looking information or
statements (collectively, “forward-looking statementsâ€) within the
meaning of applicable securities legislation. Forward-looking
statements, including those identified by the expressions “anticipateâ€,
“believeâ€, “planâ€, “estimateâ€, “expectâ€, “intendâ€, “mayâ€, “should†and
similar expressions to the extent they relate to the Company or its
management. This press release contains forward- looking statements
including those relating to the entering into of the Definitive
Agreement and closing of the Transaction with Nevada Botanical Science,
Inc. Forward-looking statements are based on the reasonable assumptions,
estimates, analysis and opinions of management made in light of its
experience and its perception of trends, current conditions and expected
developments, as well as other factors that management believes to be
relevant and reasonable in the circumstances at the date that such
statements are made, but which may prove to be incorrect.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
performance or achievements of the Company to differ materially from any
future results, performance or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the risk factors included in the Company’s final long form
prospectus dated August 21, 2018, which is available under the
Company’s SEDAR profile at www.sedar.com.
Accordingly, readers should not place undue reliance on any such
forward-looking statements. Further, any forward-looking statement
speaks only as of the date on which such statement is made. New factors
emerge from time to time, and it is not possible for the Company’s
management to predict all of such factors and to assess in advance the
impact of each such factor on the Company’s business or the extent to
which any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. The Company does not undertake any obligation to update any
forward-looking statements to reflect information, events, results,
circumstances or otherwise after the date hereof or to reflect the
occurrence of unanticipated events, except as required by law including
securities laws. This news release does not constitute an offer to sell
or a solicitation of any offer to buy any securities of the Company.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT: North Bud Farms Inc. Edward Miller VP, IR & Communications Office: (855) 628-3420 ext. 3 [email protected]
Posted by AGORACOM-JC
at 5:37 PM on Monday, November 18th, 2019
SPONSOR: NORTHBUD (NBUD:CSE)
Sustainable low cost, high quality cannabinoid production and
procurement focusing on both bio-pharmaceutical development and
Cannabinoid Infused Products. Learn More.
THC-infused edibles and CBD-infused edibles
When cannabis is ingested, the THC is metabolized by the liver
With edibles coming to brick-and-mortar shops in mid-December, users are looking to get high without the smoke.
But when choosing edibles, users will want to pay attention to
whether the product has CBD or THC, two compounds with very different
effects.
CBD
CBD, the non-psychoactive component within cannabis has been widely
touted for its medical benefits to help people with, among other
conditions, chronic pain. The World Health Organization (WHO) reports
CBD is not physically addictive.
By comparing those administered doses of active CBD to those given as
a placebo, researchers said that “while the number of studies is
limited, the evidence from well-controlled human experimental research
indicates that CBD is not associated with abuse potential.â€
CBD leads to slower effects that aren’t psychoactive in
nature — meaning they aren’t the effects you see portrayed in pop
culture.
The effects from CBD will be tame and mellow compared to its
psychoactive opposite, THC. Most medical cannabis includes CBD rather
than THC, with CBD already available in capsule form in legal stores.
THC
When most people think of cannabis’ effects, they think of THC. Many
of the new cannabis products slated to enter stores in mid-December will
focus on THC.
When cannabis is ingested, the THC is metabolized by the liver,
transforming itself into 11-hydroxy-THC. This metabolite is up to four
times faster in crossing the blood-brain barrier than average THC, and
is why edibles are associated with intense, vivid and longer-lasting
experiences.
THC normally gets pointed at as the compound that creates the potential for withdrawal symptoms among some heavy users.
An evidence brief compiled by the Canadian Public Health Association (CPHA) states that “cannabis is addictive, though not everyone who uses it will develop an addiction.â€
While using cannabis oil or edibles with THC, users may get addicted
or experience habit-formation. Products that only include CBD don’t
appear to become addictive.
Posted by AGORACOM-JC
at 12:49 PM on Monday, November 18th, 2019
Senior Management including; Andrew Ryu, Jeffrey Stevens and Steve Kang have voluntarily agreed to reduce their compensation by approximately 40% effective immediately
Additionally, the Company’s 10% rolling stock option plan was re-approved and confirmed
Shareholders passed a special resolution to change the name of the Company from Datametrex AI Limited to Nexalogy AI Limited as well as a share consolidation plan of up to 8 to 1Â
TORONTO, Nov. 18, 2019 – Datametrex AI Limited (the “Company†or “Datametrexâ€) (TSXV: DM, FSE: D4G) is pleased to announce that the Senior Management including; Andrew Ryu, Jeffrey Stevens and Steve Kang have voluntarily agreed to reduce their compensation by approximately 40% effective immediately. The Company also completed the integration of back office functions of Nexalogy. As a result, the Company has cut down the number of staff and office space as a part of its cost saving strategy.
“Our goal is to grow the business and share price organically rather
than doing a share consolidation. The entire team is aligned with our
shareholders in getting the Company back on track,†says Marshall
Gunter, CEO of the Company.
The Company is also pleased to announce completion of it’s annual and
special meeting. At the meeting, Andrew Ryu, Charles Schade, Janeen
Stodulski, David Ellison and John McMullen were elected as directors of
the Company and KPMG were appointed as auditors for the Company.
Additionally, the Company’s 10% rolling stock option plan was
re-approved and confirmed and shareholders passed a special resolution
to change the name of the Company from Datametrex AI Limited to Nexalogy
AI Limited as well as a share consolidation plan of up to 8 to 1.
The Company’s name will not be changed until the Company files
articles of amendment and obtains the necessary regulatory approvals.
While the resolution gives discretion to the Company’s board and
management to effect the share consolidation, no decision has been made
by the Company to complete the consolidation or what the consolidation
ratio will be. If and when the Company decides to implement the share
consolidation, a further press release will be disseminated with the
details of the share consolidation.
About Datametrex
Datametrex AI Limited is a technology focused company with exposure
to Artificial Intelligence and Machine Learning through its wholly owned
subsidiary, Nexalogy (www.nexalogy.com).
For further information, please contact:
Jeff Stevens – President Phone: 647-777-7974 Email: [email protected]
Forward-Looking Statements
This news release contains “forward-looking information†within
the meaning of applicable securities laws. All statements contained
herein that are not clearly historical in nature may constitute
forward-looking information. In some cases, forward-looking information
can be identified by words or phrases such as “mayâ€, “willâ€, “expectâ€,
“likelyâ€, “shouldâ€, “wouldâ€, “planâ€, “anticipateâ€, “intendâ€,
“potentialâ€, “proposedâ€, “estimateâ€, “believe†or the negative of these
terms, or other similar words, expressions and grammatical variations
thereof, or statements that certain events or conditions “may†or “willâ€
happen, or by discussions of strategy.
Readers are cautioned to consider these and other factors,
uncertainties and potential events carefully and not to put undue
reliance on forward-looking information. The forward-looking information
contained herein is made as of the date of this press release and is
based on the beliefs, estimates, expectations and opinions of management
on the date such forward-looking information is made. The Company
undertakes no obligation to update or revise any forward-looking
information, whether as a result of new information, estimates or
opinions, future events or results or otherwise or to explain any
material difference between subsequent actual events and such
forward-looking information, except as required by applicable law.
Posted by AGORACOM-JC
at 11:38 AM on Monday, November 18th, 2019
SPONSOR: CardioComm Solutions (EKG: TSX-V)
– The heartbeat of cardiovascular medicine and telemedicine. Patented
systems enable medical professionals, patients, and other healthcare
professionals, clinics, hospitals and call centres to access and manage
patient information in a secure and reliable environment.
Congress Eyes Privacy Protections for Data on mHealth Wearables
A bill introduced this week – and another introduced this past June –
aim to protect patient health data gathered on consumer-facing mHealth
wearables like smartwatches, fitness bands and even apps.
US Senators Bill Cassidy (R-LA) and Jacky Rosen (D-NV) have introduced a bill this week that aims to define how data gathered on smartwatches, fitness bands and other connected health devices – including mHealth apps – dis protected and prevent “entities that collect consumer health information†from exposing that data to other parties.
November 15, 2019 – Congress is jumping into the long-simmering
debate over the protection of health data on consumer-facing mHealth
wearables.
US Senators Bill Cassidy (R-LA) and Jacky Rosen (D-NV) have introduced a bill this week
that aims to define how data gathered on smartwatches, fitness bands
and other connected health devices – including mHealth apps – dis
protected and prevent “entities that collect consumer health
information†from exposing that data to other parties.
“The introduction of technology to our health care system in the form
of apps and wearable health devices has brought up a number of
important questions regarding data collection and privacy,†Rosen said in a press release
announcing the bill, to be called The Stop Marketing And Revealing The
Wearables And Trackers Consumer Health (SMARTWATCH) Data Act. “This
commonsense, bipartisan legislation will extend existing health care
privacy protections to personal health data collected by apps and
wearables, preventing this data from being sold or used commercially
without the consumer’s consent.â€
The bill’s introduction comes amidst a flurry of news in the
consumer-facing mHealth arena, including Google’s pending purchase of
Fitbit and the announcement that the tech giant will be working with Ascension
– the largest non-profit health system in the US – to integrate mHealth
technology and data collection into the health system’s care programs.
“The Google/Ascension news has brought needed scrutiny to the
security of Americans’ health data,†Cassidy said in the press release.
“The SMARTWATCH Act prevents big tech data harvesters from collecting
intimate private data without patients’ consent. Americans should always
know their health information is secure.”
The bill defines consumer health information as “any information
about the health status, personal biometric information, or personal
kinesthetic information (such as keystroke or gait patterns and sleep
information) about a specific individual that is created or collected by
a personal consumer device, whether detected from sensors or input
manually.†This would include not only physiological, biological and
behavioral data, but “deoxyribonucleic acid, imagery of the iris,
retina, fingerprint, face, hand, palm, vein patterns, and voice
recordings, from which an identifier template, such as a faceprint, a
minutiae template, or a voiceprint, can be extracted.â€
Under the bill, the organization that collects that data would be
barred from transferring, selling, sharing or allowing access to that
data, unless aggregated and anonymized, to “any domestic information
broker or other domestic entity†whose primary function is to analyze
that information for profit or whose primary purpose is to add
commercial value to the entity collecting the data.
The legislation mirrors a bill introduced in June by Senators Amy
Klobuchar (D-MN) and Lisa Murkowski (R-AK) that aims to protect consumer
health information not protected under current laws.
The Protecting Personal Health Data Act (S.1842)
would require the development of regulations that strengthen privacy
and security protections, including setting consent standards that
address genetic, biometric and general personal health data, and give
consumers the ability to access, amend and delete their data. It would
also create a National Task Force on Health Data Protection that would:
evaluate and provide input to address cybersecurity risks and
privacy concerns associated with consumer products that handle personal
health data, and the development of security standards for consumer
devices, services, applications, and software; and
study the long-term effectiveness of de-identification methodologies
for genetic and biometric data, and advise on the creation of resources
to educate consumers about direct-to-consumer genetic testing.
Tags: EKG, mhealth, small cap stocks, stocks, tsx, tsx-v Posted in CardioComm Solutions | Comments Off on CardioComm Solutions $EKG.ca – Congress Eyes Privacy Protections for Data on #Mhealth #Wearables $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca
Posted by AGORACOM-JC
at 10:14 AM on Monday, November 18th, 2019
Investment Highlights
Kenbridge property has a measured and indicated resource of 7.14 million tonnes at 0.62% nickel, 0.33% copper
17.5 (21.8 fully diluted) percent equity stake in Eloro Resources and 2 percent NSR in their La Victoria property
Kenbridge Ni Project (ON, Canada)
Advanced stage deposit remains open in three directions, is
equipped with a 623m deep shaft and has never been mined.
Preliminary Economic Assessment completed and updated returned robust project economics and operating costs including a NPV of C$253M and cash costs of US$3.47/lb of nickel net of copper credits.
Plans for Kenbridge include updating PEA,
advancing the project through to feasibility and exploring the open
mineralization at depth
FULL DISCLOSURE: Tartisan Nickel Corp. is an advertising client of AGORA Internet Relations Corp.
Posted by AGORACOM-JC
at 5:05 PM on Friday, November 15th, 2019
SPONSOR: PRIMO NUTRACEUTICALS INC.
(CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV)
provides strategic capital to the thriving cannabis cultivation
sector through ownership and development of commercial real estate
properties. The company also offers fully built out turnkey facilities
equipped with state-of-the-art growing infrastructure to cannabis
growers and processors. Click here for more info.
Feds Finally Crafting National CBD Rules
After years of states passing their own rules concerning cannabidiol – more commonly known as CBD – the federal government is now quietly taking the first steps to regulate it.
Photo: Sven Hoppe/dpa (Photo by Sven Hoppe/picture alliance via Getty Images)
dpa/picture alliance via Getty Images
The F&B industry is ahead of them: You can already get CBD in
gummies, oils, lotions and juices, and Arizona Iced Tea and Ben and
Jerry’s have been testing it. But as states moved to regulate, the
federal government sat on the sidelines, leaving CBD in legal limbo.
That began to change a couple of weeks ago in what could be the
beginning of the biggest change for the CBD market since the Farm Bill
of 2018 ended classifying hemp and products derived from it as
controlled substances.
The United States Department of Agriculture (USDA) in late October
published its interim final rules for domestic hemp production in the
Federal Register, including rules regarding CBD, a product of hemp. How
big a deal could this be? Think about the end of Prohibition. The
federal government is finally creating standards that could help create a
national marketplace. That could help move CBD from the margins to the
mainstream, adding security, safety and consistency to manufacturing.
The proposed rules come as sales of CBD are expected to reach $13
billion this year, even as federal law tries to catch up with demand.
CBD is getting too big to be ignored, and lack of reliable information
and uniform regulation adds to confusion. The feds are finally arriving
on the scene (let’s not call it a party) with the structure that’s
needed.
The new rules would include federal aid for hemp farmers and could
help ease access to insurance and loans, leading to bigger supply and
more financing. There are also tough provisions, which could be good for
consumers and companies, but will add costs for manufacturers and
others in the supply chain. Hemp samples, for instance, would have to be
delivered to DEA-certified labs 15 days before harvest and certified.
The USDA, however, is only the first federal agency to lay its hands
on hemp and CBD. The Food & Drug Administration (FDA), which
approved seizure drug Epidolex containing CBD, classifies it as an
active ingredient in medications – which it regulates. The agency in
late October said it’s continuing “to explore potential pathways for
various types of CBD products to be lawfully marketed.†Manufacturing
isn’t currently subject to FDA review. The USDA’s actions could help
change that. The Grocery Manufacturers Association, for instance, is
pushing for the FDA to issue final CBD rules instead of allowing “a maze
of inconsistent, and often contradictory, state and local regulationsâ€
that can lead to a “regulatory mess.â€
The USDA has also begun to regulate THC, the psychoactive ingredient
in hemp sometimes included with CBD. The USDA indicates that,
potentially, hemp could contain up to 0.3 percent THC or
tetrahydrocannabinol, the limit in Canada and many other countries. The
FDA is likely to fall in line with that as CBD becomes more common.
CBD’s popularity comes with often-exaggerated claims; some people
look at it as a cure-all. That also could change with regulation. The
FDA already issued warnings to companies making medical claims. As the
feds begin to regulate CBD, some misinformation may vanish from
marketing, which could lower sales, as the market sorts itself out,
“weeding out†certain companies as others grow.
Money is already flowing into companies working with CBD. Altria,
parent of cigarette giant Philip Morris, poured $1.8 billion into
cannabis company Cronos Group. Beer distributors and Arizona Iced Tea
are infusing drinks with CBD, hoping to experience (puns are just too
easy here) higher sales. As the market for CBD continues to expand, it’s
only a matter of time before CBD gets what the Grocery Manufacturers
Association wished for: federal regulation.
While most industries dread regulation, it could prove essential for
CBD to truly take off in food and beverage, providing safety to
consumers and security for producers. The USDA has stepped off the
sidelines, and the FDA is talking about stepping in. It looks like
federal rules may finally be arriving, bringing standards and — get
ready — red tape (which means compliance costs) in a trade-off for
quality control, consumer protection, and growth prospects. It’s
starting to look like a national marketplace for CBD may no longer be a
pipe dream.
Posted by AGORACOM-JC
at 3:30 PM on Friday, November 15th, 2019
SPONSOR: New Age Metals Inc.
The company’s Lithium Division has already made significant
acquisitions in Canada and the USA. The company also owns one of North
America’s largest primary platinum group metals deposit in Sudbury,
Canada. Updated NI 43-101 Mineral Resource Estimate 2,867,000 PdEq
Measured and Indicated Ounces, with an additional 1,059,000 PdEq Ounces
in the Inferred. Learn More.
Europe EVs now use 57% more lithium carbonate equivalent
Changing mix of EV sales is most noticeable in Europe where the average battery in new passenger EVs sold in September contained 15.8kg of LCE
Constitutes a 57% surge compared to last year, thanks in no small part to the popularity of the Tesla Model 3 on the continent
Electric car pioneer Tesla is already producing units on a trial basis at its giant Shanghai gigafactory despite only breaking ground this year, but thanks to changes to the Chinese EV subsidy program, demand for locally-made Teslas may fall short of expectations.
On Monday, China’s automobile manufacturing industry body said fewer
new energy vehicles, or NEVs as they are termed domestically, could be
sold this year than in 2018 (last year sales boomed by more than 60%).
Sales of NEVs – which apart from battery-powered vehicles also
include hybrids and fuel cell cars – fell by more than 45% in October
from the same month last year, adding to the woes of an industry coping
with 16 straight months of declining overall sales.
Changes to China’s EV incentive program favour hybrids so lithium loads may start to tend downwards in that country too
Adamas Intelligence tracks the battery capacity (and the metals used in them)
of electric vehicles sold around the world and the slowdown in the EV
market, where lithium-ion batteries dominate, has already showed up in
raw material deployment data.
In September 2019, the average new passenger EV including plug-in and
conventional hybrids sold globally contained 12.2 kilograms of lithium
carbonate equivalent (LCE), a modest increase of 4% over 2018, according
to the latest Adamas report.
The Toronto-based research company’s data shows China still
outstripped global growth in September with a 7% increase in LCE on a
per-EV basis, reaching a sales-weighted average of just shy of 20kg
thanks to the prevalence of full electric models in the country.
That’s in stark contrast to Japan, where hybrids represent more than
90% of EV sales and average batteries contain only 1.1kg of LCE. Changes
to China’s EV incentive program favour hybrids so lithium loads may
start to tend downwards in that country too.
The changing mix of EV sales is most noticeable in Europe where the
average battery in new passenger EVs sold in September contained 15.8kg
of LCE.
That constitutes a 57% surge compared to last year, thanks in no
small part to the popularity of the Tesla Model 3 on the continent.
Teslas have always had bigger batteries than competitor cars to help
with fast-charging and range.
In the US the trend is in the opposite direction – with passenger EVs
leaving showrooms containing on average 15.2kg of LCE, 12% less than in
September 2018.
